Yahoo · Oct 15, 2026
Why Healthcare Stocks Are Hot When the AI Trade Runs Cold
Healthcare—particularly equipment and services and pharmaceuticals—offers investors diversification from AI, according to one report.
CO
NASDAQ · CORT
Corcept Therapeutics Incorporated
Healthcare · Biotechnology
$107.50
Down-$21.64 (-20.13%)
Updated Oct 23, 2026, 10:06 PM
SID Score
5.2/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 9.17B
- P/E ratio
- 85.77
- Dividend yield
- 0.00%
- 52-week range
- $28.66 – $126.38
- Volume
- 809.88K
- Avg. volume
- 846.24K
Price performance · CORT
CORT price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 22, 2026
CORT closed at $107.50 after 21 trading sessions, down 9.29% for the selected period.
- Last close
- $107.50
- Period change
- -9.29%
- Period low
- $107.50
- Period high
- $122.03
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 22, 2026 | $115.16 | $115.73 | $107.3269 | $107.50 | 809.88K |
| Oct 21, 2026 | $116.45 | $118.42 | $116.10 | $116.28 | 516.77K |
| Oct 20, 2026 | $112.60 | $117.135 | $111.955 | $116.45 | 549.57K |
| Oct 19, 2026 | $111.70 | $113.09 | $110.50 | $112.10 | 392.85K |
| Oct 16, 2026 | $113.17 | $113.635 | $107.7902 | $110.16 | 849.97K |
| Oct 15, 2026 | $116.31 | $117.4792 | $113.0201 | $113.37 | 668.52K |
| Oct 14, 2026 | $117.94 | $122.2099 | $115.95 | $116.23 | 691.96K |
| Oct 13, 2026 | $121.83 | $122.8087 | $117.4201 | $117.80 | 556.29K |
| Oct 12, 2026 | $121.24 | $122.09 | $119.28 | $121.19 | 497.74K |
| Oct 9, 2026 | $118.00 | $122.34 | $117.41 | $121.19 | 624.21K |
| Oct 8, 2026 | $118.56 | $119.155 | $115.80 | $118.54 | 496.67K |
| Oct 7, 2026 | $119.00 | $121.9999 | $117.23 | $119.60 | 634.88K |
| Oct 6, 2026 | $122.20 | $122.5399 | $115.11 | $119.57 | 790.54K |
| Oct 5, 2026 | $115.59 | $122.81 | $115.50 | $122.03 | 1M |
| Oct 2, 2026 | $114.38 | $117.315 | $113.90 | $116.23 | 960.16K |
| Oct 1, 2026 | $114.29 | $115.98 | $111.94 | $114.025 | 878.99K |
| Sep 30, 2026 | $114.80 | $118.0659 | $113.98 | $115.23 | 910.31K |
| Sep 29, 2026 | $115.92 | $120.51 | $113.16 | $114.74 | 964.47K |
| Sep 28, 2026 | $116.00 | $117.07 | $114.36 | $115.63 | 1.16M |
| Sep 25, 2026 | $119.00 | $120.44 | $114.51 | $116.10 | 800.8K |
| Sep 24, 2026 | $111.86 | $119.15 | $111.68 | $118.51 | 983.63K |
Latest CORT news
The latest Smart Investors Daily articles mentioning CORT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CORT research
Overview
Company profile and research snapshot.
Company profile
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $140.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 18, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 30, 2026 | Canaccord Genuity | Buy | — |
| Jul 30, 2026 | Piper Sandler | Overweight | — |
| Jul 30, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 29, 2026 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 15, 2026
Corcept Therapeutics (CORT) Stock Looks Fully Priced For Its Sales Story
Corcept Therapeutics has delivered very strong long term returns, which naturally raises a harder question for you as an investor. Is the current share price mainly a reflection of the company’s sales profile, or has the stock run further than its revenue base can comfortably explain? Over the past 5 years, Corcept Therapeutics has returned about 7x, so a lot of future expectations are already tied to what its sales can support. The business is heavily focused on a narrow set of therapies,...
Yahoo · Oct 15, 2026
Corcept Therapeutics (CORT) Draws Options Attention, Is It Still 18% Below Fair Value?
Corcept Therapeutics (CORT) is back in focus after options traders clustered around the November 20, 2026 $47.50 put, which recently showed some of the highest implied volatility among individual equity contracts. Recent trading tells a mixed story for Corcept Therapeutics. The share price is down 1.33% over the past day and 2.82% over the past week, yet it has gained 29.55% over 90 days and the year-to-date share price return is 204.27%. Over the longer term, the 5-year total shareholder...
Yahoo · Oct 6, 2026
Corcept, IBD Stock Of The Day, Setting Up Amid Booming Earnings Growth
Corcept Therapeutics, Stock Of The Day fell amid a medical sell-off, but has pared losses to near buy points. Earnings growth is booming.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
